neuropathic pain
Conditions
Interventions
An initial dose of pregabalin at 25 mg
this was then increased up to a maximum of 150 mg.
Sponsors
Nihon University School of Medicine Divisions of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Hemodialysis duration > 6 months at enrollment. Patients who could make a decision. Patients who were diagnosed with peripheral neuropathic pain by a neurologist.
Exclusion criteria
Exclusion criteria: (1) age < 20 years or > 85 years, (2) a history of severe heart failure, angina, myocardial infarction, or stroke within the past 6 months, (3) the presence of infectious disease, thyroid disease, malignant tumors, or treatment with steroids or immunosuppressants, (4) current hospitalization, (5) patients with a history of angioedema, and (6) patients with dementia who experience difficulty making a decision
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS(baseline and 12 weeks) | — |
Secondary
| Measure | Time frame |
|---|---|
| SF-8,HS-CRP(baseline and 12 weeks) Blood cell counts, levels of serum creatinine, serum urea nitrogen, total protein, albumin, electrolytes, total cholesterol, low-density lipoprotein cholesterol, triglyceride, serum iron, total iron binding capacity, serum ferritin, high-sensitivity C-reactive protein, serum beta-2-microglobulin, intact parathyroid hormone Kt/V systolic and diastolic blood pressure, heart rate, cardiothoracic ratio adverse events | — |
Countries
Japan
Contacts
Public ContactTomoyasu Otsuki
Nihon University School of Medicine Divisions of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine
Outcome results
None listed